AKAyşe Nur Keleş

Ayşe Nur Keleş

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ayşe Nur Keleş has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Protective Effects of Dabrafenib on Doxorubicin-Induced Cardiotoxicity in Rats

    by Meryem Şeyda Kaya, Meral Erdinç, Zeynep Erdoğmuş Özgen, İlker Kelle, Fesih Aktar, Levent Erdinç, Ayşe Nur Keleş, Mehmet Küçüköner

    Doxorubicin (DOX) is a commonly used antineoplastic agent whose clinical use is mainly limited by its cardiotoxicity. Since necroptosis has been implicated in DOX-induced cardiotoxicity, this study investigated and compared the protective effects of dabrafenib (Dab), a RIPK3 inhibitor, and necrostatin-1 (Nec-1), a RIPK1 inhibitor, targeting two key components of the necroptotic signaling pathway. Thirty-six male Sprague–Dawley rats were divided into four groups: control, DOX, DOX+Dab, and DOX+Nec-1. Coronary perfusion pressure was assessed in isolated hearts using the Langendorff system, while serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels, cardiac malondialdehyde (MDA) levels, histopathological alterations, and the expression of necroptosis-related proteins were analyzed. DOX treatment significantly increased coronary perfusion pressure, serum CK and LDH levels, cardiac MDA levels, and RIPK1, RIPK3, and mixed lineage kinase domain-like protein (MLKL) expression and induced marked histopathological damage. Both dabrafenib and Nec-1 attenuated these alterations and histopathological damage, although the magnitude of their effects varied across the measured outcomes. No significant differences in serum CK or LDH levels were observed between the two treatment groups. Overall, our findings suggest that dabrafenib may attenuate DOX-induced cardiac injury, although its effects on necroptotic signaling remain to be established.

  • Open Access

    EBP50 and Merlin Expression Across the Spectrum of Serous Ovarian Tumors: Clinicopathological Associations and Exploratory Diagnostic Value

    by Ayşe Nur Keleş, İsmail Yildiz, Reyhan Gündüz, Zuhat Urakçi, Ulaş Alabalik

    Background: Serous ovarian tumors comprise biologically distinct entities ranging from benign and borderline tumors to low-grade (LGSC) and high-grade serous carcinoma (HGSC). EBP50/NHERF1 and Merlin/NF2 regulate epithelial polarity, membrane–cytoskeletal organization, and signaling. We evaluated EBP50 and Merlin expression across the spectrum of serous ovarian tumors, explored their clinicopathological and diagnostic associations, and compared these findings with Ki67 and mitotic activity in serous carcinomas. Methods: EBP50 and Merlin immunoreactivity was evaluated in serous cystadenomas, serous borderline tumors (SBTs), LGSCs, and HGSCs. Ki67 and mitotic activity were assessed in malignant tumors. Exploratory discriminatory performance was evaluated by receiver operating characteristic analysis, and overall survival by Kaplan–Meier and Cox proportional hazards analyses. Results: EBP50 expression differed significantly among tumor groups (p < 0.001), with the lowest expression and most frequent complete loss in HGSC. EBP50 showed moderate discrimination between carcinomas and non-carcinoma tumors (AUC = 0.790) and lower expression was associated with more advanced disease, including higher FIGO stage. Merlin expression also differed among groups (p = 0.003) but showed limited discriminatory performance (AUC = 0.605). Ki67 and mitotic activity strongly distinguished LGSC from HGSC (AUC = 0.992 for both). Although Ki67 was associated with poorer overall survival in univariable analysis, none of the biomarkers independently predicted survival after adjustment for age and FIGO stage. Conclusions: EBP50 showed potentially useful differences in expression across serous ovarian tumor categories and may provide adjunctive information in selected diagnostic settings, whereas the diagnostic contribution of Merlin appeared limited. Ki67 and mitotic activity confirm the established proliferative distinction between LGSC and HGSC. Further validation of EBP50 and Merlin in independent cohorts is warranted.

  • Open Access

    The Role of Hemogram Parameters in Differentiating Malignant from Benign Thyroid Nodules

    by Eşref Araç, Erhan Şimşek, Muhammed Akif Deniz, Ayşe Nur Keleş

    Introduction and Objectives: Thyroid nodules are a common clinical finding, with over 90% being benign and approximately 4-6.5% exhibiting malignant characteristics. Fine-needle aspiration biopsy (FNAB) under ultrasound guidance is the standard diagnostic method. This study aimed to evaluate the role of routine hemogram parameters in distinguishing between benign and malignant thyroid nodules in patients who underwent FNAB due to suspicion of malignancy. Materials and Methods: This retrospective study included 80 patients who underwent thyroid FNAB at the Interventional Radiology and Endocrinology Clinic of Dicle University Faculty of Medicine Hospital between September 2022 and November 2024, with results reported as either malignant or benign. Demographic characteristics and hemogram parameters, including neutrophil, lymphocyte, platelet counts, hemoglobin, and derived ratios (NLR, PLR, NPL), were analyzed and compared between the benign and malignant groups. Results: Of the 80 patients, 77.5% (n=62) were female and 22.5% (n=18) were male. The mean age was 50.6 ± 12.54 years, with 82.5% (n=66) aged ≥40 years. Based on FNAB results, 60% (n=48) were benign and 40% (n=32) were malignant. Although the malignant group had higher mean values for neutrophil count, NLR, NPL, and PLR compared to the benign group, these differences were not statistically significant (p>0.05). Similarly, no significant differences in hemogram parameters were found when comparing groups by gender or age. However, malignancy rates were significantly higher in males (61.1% vs. 33.9% in females, p=0.038) and in patients under 40 years of age (64.3% vs. 34.8% in ≥40 group, p=0.041). Conclusion: This study found that hemogram parameters did not show a statistically significant ability to differentiate between benign and malignant thyroid nodules. However, male gender and younger age (<40 years) were identified as significant demographic risk factors for malignancy. Further large-scale, multicenter prospective studies are needed to clarify the potential prognostic or supportive role of hemogram parameters in thyroid nodule evaluation.

  • Open Access

    Can EBP50 and Merlin be used as diagnostic and prognostic markers for uterine smooth muscle tumors?

    by Ulaş Alabalik, Ayşe Nur Keleş, Reyhan Gündüz, Zuhat Urakçı, İsMail Yıldız


  • Radyolojik ve patolojik tanısı konan safra kesesi fibromu: Olgu sunumu ve literatür taraması

    by İbrahim İbi̇loglu, Ulaş ALABALIK, Gül Türkçü, Ayşe Nur KELEŞ, Alpay Çeti̇n

    Fibromlar, vücudun herhangi bir yerinde özelliklede diz ve parmaklarda görülen, yavaş büyüyen, ağrısız ve sert kitlelerdir. Safra kesesi fibroması nadir bir tümör olup literatürde sadece birkaç adet olgu sunumu olarak yer almaktadır. Biz burada ultrasonografi ve manyetik rezonans kolanjiyografide preoperatif olarak safra kesesi polipi tanısı konan 49 yaşında bir kadın hastayı sunmayı amaçladık. Kolesistektomi spesmeni hidropik görünümde olup kesitlerinde kese boynunda polipoid bir kitle izlendi. Mikroskobik olarak nodül, kollajenöz stromada oval yuvarlak şekilli hücrelerden oluşuyordu. Stromal hücreler Vimentin ile pozitif immünreaktivite gösterdi; Desmin, S-100, SMA ve CD34 negatifti. Lezyonu safra kesesi fibromu olarak teşhis ettik. Literatürde safra kesesi fibromu tanısı alan iki olgu bulunmaktadır.